RATIONALE: Interferon-γ (IFN-γ) release assays are widely used to diagnose latent infection with Mycobacterium tuberculosis in adults, but their performance in children remains incompletely evaluated to date. OBJECTIVES: To investigate factors influencing results of IFN-γ release assays in children using a large European data set. METHODS: The Pediatric Tuberculosis Network European Trials group pooled and analyzed data from five sites across Europe comprising 1,128 children who were all investigated for latent tuberculosis infection by tuberculin skin test and at least one IFN-γ release assay. Multivariate analyses examined age, bacillus Calmette-Guérin (BCG) vaccination status, and sex as predictor variables of results. Subgroup analyses included children who were household contacts. MEASUREMENTS AND MAIN RESULTS: A total of 1,093 children had a QuantiFERON-TB Gold In-Tube assay and 382 had a T-SPOT.TB IFN-γ release assay. Age was positively correlated with a positive blood result (QuantiFERON-TB Gold In-Tube: odds ratio [OR], 1.08 per year increasing age [P < 0.0001]; T-SPOT.TB: OR, 1.14 per year increasing age [P < 0.001]). A positive QuantiFERON-TB Gold In-Tube result was shown by 5.5% of children with a tuberculin skin test result less than 5 mm, by 14.8% if less than 10 mm, and by 20.2% if less than 15 mm. Prior BCG vaccination was associated with a negative IFN-γ release assay result (QuantiFERON-TB Gold In-Tube: OR, 0.41 [P < 0.001]; T-SPOT.TB: OR, 0.41 [P < 0.001]). Young age was a predictor of indeterminate IFN-γ release assay results, but indeterminate rates were low (3.6% in children < 5 yr, 1% in children > 5 yr). CONCLUSIONS: Our data show that BCG vaccination may be effective in protecting children against Mycobacterium tuberculosis infection. To restrict use of IFN-γ release assays to children with positive skin tests risks underestimating latent infection.
RATIONALE: Interferon-γ (IFN-γ) release assays are widely used to diagnose latent infection with Mycobacterium tuberculosis in adults, but their performance in children remains incompletely evaluated to date. OBJECTIVES: To investigate factors influencing results of IFN-γ release assays in children using a large European data set. METHODS: The Pediatric Tuberculosis Network European Trials group pooled and analyzed data from five sites across Europe comprising 1,128 children who were all investigated for latent tuberculosis infection by tuberculin skin test and at least one IFN-γ release assay. Multivariate analyses examined age, bacillus Calmette-Guérin (BCG) vaccination status, and sex as predictor variables of results. Subgroup analyses included children who were household contacts. MEASUREMENTS AND MAIN RESULTS: A total of 1,093 children had a QuantiFERON-TB Gold In-Tube assay and 382 had a T-SPOT.TB IFN-γ release assay. Age was positively correlated with a positive blood result (QuantiFERON-TB Gold In-Tube: odds ratio [OR], 1.08 per year increasing age [P < 0.0001]; T-SPOT.TB: OR, 1.14 per year increasing age [P < 0.001]). A positive QuantiFERON-TB Gold In-Tube result was shown by 5.5% of children with a tuberculin skin test result less than 5 mm, by 14.8% if less than 10 mm, and by 20.2% if less than 15 mm. Prior BCG vaccination was associated with a negative IFN-γ release assay result (QuantiFERON-TB Gold In-Tube: OR, 0.41 [P < 0.001]; T-SPOT.TB: OR, 0.41 [P < 0.001]). Young age was a predictor of indeterminate IFN-γ release assay results, but indeterminate rates were low (3.6% in children < 5 yr, 1% in children > 5 yr). CONCLUSIONS: Our data show that BCG vaccination may be effective in protecting children against Mycobacterium tuberculosis infection. To restrict use of IFN-γ release assays to children with positive skin tests risks underestimating latent infection.
Authors: R Diel; D Goletti; G Ferrara; G Bothamley; D Cirillo; B Kampmann; C Lange; M Losi; R Markova; G B Migliori; A Nienhaus; M Ruhwald; D Wagner; J P Zellweger; E Huitric; A Sandgren; D Manissero Journal: Eur Respir J Date: 2010-10-28 Impact factor: 16.671
Authors: Christopher C Whalen; Sarah Zalwango; Allan Chiunda; LaShaunda Malone; Kathleen Eisenach; Moses Joloba; W Henry Boom; Roy Mugerwa Journal: PLoS One Date: 2011-02-14 Impact factor: 3.240
Authors: Deborah A Lewinsohn; Sarah Zalwango; Catherine M Stein; Harriet Mayanja-Kizza; Alphonse Okwera; W Henry Boom; Roy D Mugerwa; Christopher C Whalen Journal: PLoS One Date: 2008-10-15 Impact factor: 3.240
Authors: Jason R Andrews; Elisa Nemes; Michele Tameris; Bernard S Landry; Hassan Mahomed; J Bruce McClain; Helen A Fletcher; Willem A Hanekom; Robin Wood; Helen McShane; Thomas J Scriba; Mark Hatherill Journal: Lancet Respir Med Date: 2017-02-16 Impact factor: 30.700
Authors: E Chiappini; A Lo Vecchio; S Garazzino; G L Marseglia; F Bernardi; E Castagnola; P Tomà; D Cirillo; C Russo; C Gabiano; D Ciofi; G Losurdo; M Bocchino; E Tortoli; M Tadolini; A Villani; A Guarino; S Esposito Journal: Eur J Clin Microbiol Infect Dis Date: 2016-01 Impact factor: 3.267
Authors: Anna M Mandalakas; H Lester Kirchner; Gerhard Walzl; Robert P Gie; H Simon Schaaf; Mark F Cotton; Harleen M S Grewal; Anneke C Hesseling Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: Christian Lundtoft; Anthony Afum-Adjei Awuah; Norman Nausch; Anthony Enimil; Ertan Mayatepek; Ellis Owusu-Dabo; Marc Jacobsen Journal: Med Microbiol Immunol Date: 2017-03-15 Impact factor: 3.402
Authors: Thomas R Hawn; Tracey A Day; Thomas J Scriba; Mark Hatherill; Willem A Hanekom; Thomas G Evans; Gavin J Churchyard; James G Kublin; Linda-Gail Bekker; Steven G Self Journal: Microbiol Mol Biol Rev Date: 2014-12 Impact factor: 11.056
Authors: S Dhanasekaran; S Jenum; R Stavrum; C Ritz; J Kenneth; M Vaz; T M Doherty; H M S Grewal Journal: Genes Immun Date: 2014-04-17 Impact factor: 2.676
Authors: Beate Kampmann; James A Seddon; James Paton; Zohreh Nademi; Denis Keane; Bhanu Williams; Amanda Williams; Sue Liebeschutz; Anna Riddell; Jolanta Bernatoniene; Sanjay Patel; Nuria Martinez; Paddy McMaster; Robindra Basu-Roy; Steven B Welch Journal: Am J Respir Crit Care Med Date: 2018-04-15 Impact factor: 21.405